%0 Journal Article %T Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer¡¯s disease %A Claus Thamer %A Glen Wunderlich %A Lutz Fr£¿lich %A Michael Roehrle %A Miguel Garcia %A Jr %J Archive of "Alzheimer's Research & Therapy". %D 2019 %R 10.1186/s13195-019-0467-2 %X Putative mode of action of phosphodiesterase type 9 inhibition by BI 409306. Ca2+, calcium; cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate; LTP, long-term potentiation; NMDA-R, N-methyl-D-aspartate receptor; NO, nitric oxide; NOS, nitric oxide synthase; PDE9, phosphodiesterase type 9; sGC, soluble guanylate cyclase. Figure adapted from Moschetti et al. [7 %K Alzheimer¡¯s disease %K Treatment efficacy %K Neuropsychological test battery %K Phosphodiesterase type 9 inhibitor %K Prodromal stage %K Safety %U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371616/